⚡ Quick Start — If You Read Nothing Else

The 10 most important things to know right now.

Eczema is now controllable at every level of severity. A consistent daily skin-barrier routine plus the right medicines can bring even severe, lifelong eczema under good control. This is a dramatic change from the era when topical steroids were the only option.
Daily moisturizing is the foundation — for everyone, forever. Generous, frequent emollients and gentle “soak-and-seal” bathing protect the leaky skin barrier that drives eczema. This base layer of care never stops, even when you add medicines.
Topical steroids are safe when used correctly. Used at the right strength, for the right length of time, and increasingly in a proactive twice-weekly “maintenance” pattern, they are a cornerstone of care. Fear of steroids (“steroid phobia”) leads to undertreatment and more flares.
Steroid-free creams expand your options. Calcineurin inhibitors (tacrolimus, pimecrolimus), crisaborole, topical ruxolitinib, and newer creams (roflumilast, tapinarof) control inflammation without steroid side effects — especially helpful for the face, eyelids, and skin folds.
Biologic injections transformed moderate-to-severe disease. Dupilumab and newer biologics precisely block the immune signals (interleukin-4, -13, and -31) that drive eczema and itch. They clear skin and calm itch for many people, have a strong safety profile, need no routine blood tests, and dupilumab is approved down to 6 months of age.
Itch is now a direct treatment target. A biologic (nemolizumab) blocks the main itch signal (IL-31), and oral JAK-inhibitor pills relieve itch within days. Itch — the most distressing symptom — no longer has to be endured.
Oral JAK pills are powerful and fast, but carry serious warnings. Upadacitinib and abrocitinib work quickly for moderate-to-severe eczema. They carry a boxed warning (serious infections, blood clots, heart events, cancer, death) and need screening and monitoring, so they are chosen carefully.
Know the one true emergency. Painful, rapidly spreading clusters of blisters or “punched-out” sores — especially with fever or feeling unwell — can be eczema herpeticum, a herpes-virus infection of eczema skin. This needs same-day medical care.
Eczema is a whole-body condition. It is linked to asthma, hay fever, and food allergy (the “atopic march”), and to poor sleep and mental-health strain. Good care looks at the whole person, not just the skin.
You are an active partner in your care. Track your flares and triggers, ask questions, and don’t settle for “just live with it.” If topicals aren’t enough, ask about phototherapy, biologics, and pills — the toolkit is larger than ever.

▼ Collapse

Understanding Atopic Dermatitis: What It Is and Why You Itch

Atopic dermatitis (AD) — the most common form of eczema — is a chronic, relapsing, intensely itchy inflammatory skin disease. It affects up to about 1 in 5 children and roughly 1 in 10 adults in many countries. It can begin in infancy, childhood, or adulthood, and it tends to come and go in “flares” on top of skin that is dry and easily irritated even when calm.

Two things go wrong in eczema, and they feed each other:

A leaky skin barrier. The outer layer of eczema skin doesn’t hold moisture in or keep irritants and germs out as well as it should. (In some people this is partly genetic — for example, changes in a skin protein called filaggrin.)
An overactive immune response. A particular branch of the immune system (called “type-2” inflammation, driven by signaling proteins IL-4, IL-13, and IL-31) becomes overactive in the skin. This causes redness, swelling, and intense itch.

The result is the itch-scratch cycle: inflammation makes you itch, scratching damages the barrier further and releases more itch signals, and the eczema worsens. Breaking this cycle — with moisturizer, anti-inflammatory medicine, and itch control — is the heart of treatment.

Eczema looks different on different skin tones. On lighter skin it often appears pink or red. On brown and Black skin it may look violet, gray, or darker than the surrounding skin, with small bumps around hair follicles and lasting light or dark marks after a flare heals. This difference is real and important — eczema is sometimes under-recognized or judged “mild” in skin of color when it is actually significant. Describe how your skin feels (itch, tightness, burning), not just how it looks.

Where eczema shows up (and how it changes with age)

Infants often have it on the cheeks, scalp, and the outer surfaces of arms and legs.
Children and teens typically have it in the bends of the elbows and knees, the wrists, ankles, and neck.
Adults commonly have hand eczema, head-and-neck involvement, and thickened, leathery patches (lichenification) from years of rubbing. Some adults develop eczema for the first time.

How “how bad is it?” gets measured

Clinicians grade eczema to choose treatment and track progress. You don’t need to memorize these, but it helps to recognize the words:

EASI and SCORAD — scores doctors calculate from how much skin is involved and how red, thick, and scratched it is.
IGA — a 0–4 “global” rating (0 = clear, 4 = severe).
BSA — the percent of your body surface affected.
POEM — a questionnaire you fill out about your symptoms over the past week.
Itch NRS — you rate your worst itch from 0 to 10.
DLQI — a quality-of-life questionnaire.

Roughly speaking, eczema is called mild, moderate, or severe. Mild disease is usually handled with skin care and topical creams; moderate-to-severe disease that topicals can’t control is where phototherapy, biologics, and pills come in.

The honest, hopeful bottom line. Eczema is a long-term condition that today is highly controllable but not “cured.” With a steady routine and the right medicines, the great majority of people — children and adults — can reach clear or nearly clear skin, sleep through the night, and live comfortably and fully. Treatment is often a marathon of small consistent steps, not a single fix.

The tabs follow the usual “ladder” of eczema care, from the foundation upward:

Skin-Barrier Care & Topicals — the base for everyone.
Phototherapy — light treatment for moderate disease.
Biologics & JAK Pills — targeted systemic treatment for moderate-to-severe disease.
Itch, Sleep & Infections — symptom control and safety.
Eczema in Children & Living Well — the atopic march, family life, mental health.
Support & Resources — trials, centers, glossary, and references.

Throughout, look for Caregiver Notes and Questions to Ask Your Doctor.

If you care for a child or an adult with eczema, three things matter most from day one:

Consistency beats intensity. Moisturizing twice a day every day does more than an occasional heroic effort. Build it into routines (after bath, before bed).
Treat the itch, not just the rash. Itch drives scratching, sleeplessness, mood problems, and school/work struggles. Take it seriously.
Know your red flags (see “Itch, Sleep & Infections”): spreading painful blisters with fever = urgent care; weeping, honey-colored crusting, increasing pain = possible bacterial infection needing prompt review.

What is causing my (or my child’s) eczema, and why is the skin so itchy and inflamed?
How severe is my eczema, and how are you measuring it?
Is this definitely atopic dermatitis, or could it be something else (contact allergy, psoriasis, a fungal infection, or — rarely — something that needs a biopsy)?
What is a realistic goal for my skin over the next 3–6 months?
Given how my eczema affects my sleep, mood, work, or school, should we be more aggressive with treatment?
What should I track between visits, and when should I contact you sooner?

Important. This guide is for education and to help you have better conversations with your care team. It is not medical advice and cannot replace a clinician who can examine you and know your history. Eczema care is highly individual. Never start, stop, or change a prescription based on a guide alone.

Atopic dermatitis is fundamentally a skin-barrier defect combined with an overactive immune response. In healthy skin, a protein called filaggrin helps form a tight seal at the surface, locking in moisture and keeping irritants and allergens out. Many people with AD carry genetic variants that reduce filaggrin production — the result is a “leaky” barrier that lets moisture escape and allergens enter.

Once allergens slip through, immune cells in the skin — particularly T helper-2 (Th2) cells — release chemical signals called cytokines, especially IL-4, IL-13, and IL-31. IL-4 and IL-13 drive inflammation and further barrier damage; IL-31 activates nerve fibers in the skin and triggers intense itch. This creates a vicious cycle: inflammation weakens the barrier → more allergens enter → more inflammation → more itch → scratching → barrier damage.

This is exactly why modern treatments work at specific points in this cycle. Dupilumab, tralokinumab, and lebrikizumab block IL-4 and/or IL-13, interrupting the core inflammatory loop. Nemolizumab blocks IL-31 receptors, directly calming itch signals. JAK inhibitors block enzymes (Janus kinases) that multiple cytokines use to trigger inflammation.

What this means for you: when a new treatment takes effect, you’re not just soothing surface symptoms — you’re actually changing how your immune system communicates. The barrier can begin to heal, and long-standing inflammation can quiet. This is why many people experience dramatic improvement with targeted treatments after years of inadequate control.

Genetics explain much but not all of AD. Environmental exposures (dust mites, pet dander, mold, certain soaps and detergents), skin microbiome disruption (overgrowth of Staphylococcus aureus), sweat, stress, and extreme temperatures all act as triggers that provoke flares on top of the underlying predisposition. Your personal trigger pattern is unique, and a flare diary is one of the most useful things you can keep.

Dermatologists use standardized scoring tools to measure how severe your AD is, track whether treatments are working, and make coverage decisions for biologic therapies. Understanding these scores helps you participate in your own care.

IGA (Investigator’s Global Assessment): a simple 0–4 scale. 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe. Most insurers require IGA ≥3 (moderate) or worse for biologic approval. The key milestone is reaching IGA 0 or 1, which is considered “treatment success.”
EASI (Eczema Area and Severity Index): the most commonly used research and clinical tool. Combines affected skin area and four physical signs (redness, thickness/papulation, excoriation/scratch marks, lichenification/skin thickening) across four body regions. Score range: 0–72. Mild = <7; moderate = 7–21; severe = >21. A ≥75% reduction in EASI (EASI-75) is the standard clinical trial benchmark.
SCORAD (Scoring of Atopic Dermatitis): includes objective signs plus the patient’s own ratings of itch and sleep loss on a 0–10 scale. Range 0–103. Mild = <25; moderate = 25–50; severe = >50.
POEM (Patient-Oriented Eczema Measure): 7 questions about symptoms over the past week (itch, sleep, bleeding, weeping, cracking, flaking, dryness). Range 0–28. This is YOUR perspective, not a clinician’s exam.
DLQI (Dermatology Life Quality Index): 10 questions covering how AD affects your daily activities, relationships, work/study, leisure, and treatment side effects. Range 0–30; higher = more impacted.

At your appointments, ask your provider which score they’re using and what your current number is. If you’re starting a new treatment, knowing your baseline score lets you measure how much the treatment is actually helping. The best-studied biologic-response benchmarks are EASI-75 (at least 75% improvement from baseline) and EASI-90 (90% improvement — near-complete clearance), which many patients on dupilumab and upadacitinib achieve within 16 weeks.

Atopic dermatitis is not simply “dry skin” or “an allergy.” It is a complex immune-mediated disease that arises from a two-part problem: a defective skin barrier that lets irritants, allergens, and microbes in, and an overactive immune system that responds too aggressively when they do. Understanding these two components explains why the treatments that work best target the immune system, not just the skin surface.

The skin barrier problem: Your skin’s outermost layer (the stratum corneum) is designed to work like a tight brick wall — skin cells (bricks) held together by lipids including ceramides, free fatty acids, and cholesterol (mortar). In AD, this wall has gaps. The most studied reason is mutations or reduced function of a protein called filaggrin (FLG), which is essential for structuring the skin cells and maintaining the mortar between them. About 30–50% of people with moderate-to-severe AD have a filaggrin mutation. When the barrier is leaky, water evaporates easily (causing dryness and itch) and environmental substances that wouldn’t normally penetrate can enter the skin and trigger immune responses. This is why aggressive, consistent moisturizing is the foundation of all AD treatment — it compensates for the compromised barrier even when the immune system is already being treated.

The immune overreaction: Once allergens and irritants get through the leaky barrier, a cascade begins. Skin cells called keratinocytes release three alarm-signal proteins — TSLP (thymic stromal lymphopoietin), IL-25, and IL-33 — that activate immune cells called innate lymphoid cells (ILC2s) and dendritic cells. These cells then drive a Th2 immune response: the release of the cytokines IL-4, IL-13, and IL-31. These cytokines are the direct drivers of the AD flare: IL-4 and IL-13 suppress filaggrin production further (worsening the barrier), reduce antimicrobial peptides (allowing Staphylococcus aureus to colonize the skin), and drive the “itch-scratch cycle” through direct activation of itch nerve fibers. IL-31 directly stimulates itch nerves, explaining why AD itch is so intense and why antihistamines (which block histamine, not IL-31) are largely ineffective for AD itch.

Why this science matters for treatment choices: Dupilumab blocks the receptor that both IL-4 and IL-13 signal through (the IL-4 receptor alpha subunit, or IL-4Rα). This is why it addresses both the immune overreaction AND the barrier suppression simultaneously. Tralokinumab and lebrikizumab block IL-13 specifically. Nemolizumab blocks IL-31Rα, addressing the itch component more directly. Oral JAK inhibitors block the intracellular signaling downstream of multiple cytokine receptors at once. TCS and topical calcineurin inhibitors suppress immune activation locally. Each class targets a different point in the pathway — which is why combination approaches (topicals for local control, biologics for systemic immune regulation) are more effective than either alone.

The atopic march — why AD is not just a skin disease: The same immune dysregulation that drives AD can sensitize the immune system to allergens encountered at mucosal surfaces. Over time, children with AD have a significantly elevated risk of developing food allergy (particularly peanut and egg), allergic asthma, and allergic rhinitis (hay fever). This progression is called the atopic march. The sequence is not inevitable — not every child with AD develops asthma, and not every child with asthma had AD first. But the pattern is documented across large population studies: AD typically appears first (often in infancy), food allergy next (ages 1–3), then asthma and rhinitis (ages 3–6). The atopic march has reshaped how AD is treated in early life: aggressive early control of AD may reduce the sensitization that drives later allergic disease, though the evidence for “treating AD to prevent asthma” is still developing. The LEAP study (early peanut introduction for high-risk infants) reduced peanut allergy by 80%, showing that the timing of exposure in the context of an inflamed AD skin matters enormously for downstream sensitization.

The gut-skin axis: The gut microbiome and skin microbiome are increasingly recognized as contributors to AD severity. Lactobacillus rhamnosus supplementation in pregnancy/infancy has modest but real evidence for reducing AD in high-risk offspring (JAMA 2015 Cochrane update shows small benefit). Probiotic supplementation in established AD has less consistent evidence. Certain gut dysbiosis patterns correlate with AD severity, but the direction of causation is still being studied. The current clinical implication is limited — no specific dietary modification is evidence-based as a primary AD treatment — but the science helps explain why responses to dupilumab sometimes vary by individual microbiome composition.

Why does stress worsen AD? The brain and skin communicate through a shared set of neuropeptides and nerve pathways. Psychological stress triggers the release of cortisol, substance P, and catecholamines, which can directly activate mast cells and keratinocytes in the skin, amplifying the Th2 inflammatory signal. Chronic sleep disruption (caused by AD itch itself) also dysregulates immune function and skin barrier repair, creating a self-reinforcing loop. This is why addressing stress and sleep are therapeutic targets in AD — not just quality-of-life measures — and why behavioral interventions like CBT have demonstrated measurable improvements in itch and flare frequency in clinical trials.

Stage 1 — Daily Skin-Barrier Care & Topical Medicines (the Foundation)

Almost everything in eczema care sits on top of two habits: moisturize generously and often, and treat inflammation early with topical medicine. If these are done well, many people never need anything stronger. If you do need biologics or pills later, this foundation still matters.

Moisturizers (emollients): the non-negotiable base

Use a fragrance-free moisturizer. Thicker is generally better: ointments (like plain petrolatum) and rich creams hold moisture better than thin lotions.
Apply liberally and often — at least twice a day, and after every bath or hand wash. Most people use far too little. Adults often need a large tub (hundreds of grams) per week.
Apply within a few minutes of bathing to “seal in” water (see soak-and-seal below).
Keep moisturizing even when skin looks clear — it reduces flares.

Soak and seal. Bathe or shower in lukewarm (not hot) water for about 5–10 minutes using a gentle, fragrance-free non-soap cleanser. Pat — don’t rub — skin until just damp, apply any prescription topical to active areas, then immediately seal the whole body with moisturizer. This is one of the highest-value habits in eczema.

Find and reduce your triggers

Common irritants and triggers include soaps and fragranced products, wool and rough fabrics, heat and sweat, very dry air, stress, and sometimes specific allergens. Eczema is rarely caused by a single food, and broad food-elimination diets usually do more harm than good — talk to your clinician (and an allergist) before cutting out foods, especially in children, where unnecessary restriction can cause nutrition problems and even new food allergies.

Topical corticosteroids (“steroid creams”): used right, they’re safe and effective

Topical steroids calm inflammation and itch. They come in strengths from mild (e.g., hydrocortisone) to very strong. Key principles:

Match strength to the site and severity. Milder steroids for the face, eyelids, and skin folds; stronger ones for thick patches on the body, hands, or feet — as your clinician directs.
Use enough, for long enough, to actually clear the flare. Undertreating prolongs misery.
Proactive maintenance. Once skin is clear, applying a topical anti-inflammatory twice a week to the spots that usually flare (“hot spots”) helps prevent the next flare. This is a modern, evidence-based strategy.
Side effects from correct use are uncommon; overuse of strong steroids on delicate skin can thin it or cause stretch marks. Used as directed, the benefits far outweigh the risks.

The fingertip unit (FTU). A handy way to measure topical medicine: one FTU is the amount squeezed from a standard tube along the last segment of an adult index finger. One FTU treats about two adult palm-sized areas. Your clinician or pharmacist can tell you how many FTUs your affected areas need — this prevents both underuse (too little to work) and overuse.

Steroid-free (nonsteroidal) topical medicines

These let you control inflammation while limiting steroid use — especially valuable on the face, eyelids, and folds, and for long-term maintenance:

Calcineurin inhibitors — tacrolimus ointment and pimecrolimus cream. Steroid-free, good for sensitive areas, no skin thinning. May sting at first. They carry an old “boxed warning” about a theoretical cancer risk; after two decades of use and large studies, this risk has not been borne out, and major guidelines consider them safe and useful. Discuss the warning with your clinician for context.
Crisaborole — a steroid-free PDE4-inhibitor ointment for mild-to-moderate eczema, usable down to 3 months of age. Can cause brief stinging.
Topical ruxolitinib — a steroid-free JAK-inhibitor cream for mild-to-moderate eczema (age 12+). It works well and quickly on limited areas. Because it’s a JAK inhibitor, the label carries the class boxed warning and limits how much skin and how long you use it (short-term/intermittent, generally up to ~20% of body surface). In practice the absorbed amount is very low.
Roflumilast cream — a once-daily steroid-free PDE4 cream; the 0.15% strength is approved for ages 6+ and the 0.05% strength for ages 2–5.
Tapinarof cream — a once-daily steroid-free cream with a novel mechanism (an “aryl-hydrocarbon-receptor” agonist), approved for ages 2+, with no restrictions on how much body surface or how long it’s used.

Wet-wrap therapy for tough flares

For a bad flare, your clinician may teach wet wraps: apply moisturizer (and any prescribed topical) and cover with a damp layer of clothing or bandages under a dry layer, often overnight. This boosts hydration and medicine penetration and calms severe flares. It should be done with guidance, especially in children.

Moisturizer first habit: keep tubs in the bathroom, by the bed, and at school/daycare. Warm a dab between palms so it’s less of a shock to apply.
Order matters: apply prescription medicine to active spots, then moisturizer everywhere. (Ask your clinician about timing if unsure.)
Use the fingertip-unit guide so you apply enough — many caregivers underuse out of fear and the eczema never clears.
Distraction during application (a song, a show, a story) makes it easier for little ones.
Short nails + soft mittens at night reduce scratch damage.
Don’t fear the steroid. Steroid phobia is a leading cause of undertreated eczema. Ask for written instructions on strength, amount, and how long.

Exactly which moisturizer, how much, and how often? Can you show me what “generous” looks like?
Which steroid strength goes on which body areas, and for how many days?
Should I be using a proactive twice-weekly plan on my hot spots once I’m clear?
Is a steroid-free cream (tacrolimus/pimecrolimus, crisaborole, ruxolitinib, roflumilast, tapinarof) right for my face or folds?
What does the calcineurin-inhibitor boxed warning actually mean for me?
Can you teach me (or my child) wet-wrap therapy for flares?
How many fingertip units should I be using on my affected areas?
Should I avoid any foods or do allergy testing — or could that do more harm than good?

Moisturizers are the cornerstone of AD management — but not all moisturizers are equal, and how you apply them matters as much as what you use.

Emollient categories:

Humectants (glycerin, hyaluronic acid, urea) attract water from the environment into the outer skin layer. Great for day-to-day hydration, but they can increase transepidermal water loss if the outer layer is very compromised, so they work best combined with an occlusive.
Occlusives (petrolatum/Vaseline, mineral oil, lanolin, dimethicone) physically seal the skin to reduce water loss. Petrolatum is the gold standard for barrier repair — nothing else is as evidence-based. It’s thick and greasy but highly effective, especially overnight.
Ceramide-containing creams (CeraVe, Cetaphil Moisturizing Cream, EltaMD) aim to replenish the barrier lipids that are reduced in AD. Multiple studies show ceramide formulations can modestly reduce flare frequency when used daily. They’re a good middle ground between occlusive and cosmetically acceptable.

Application timing (the “soak and seal” method): Apply moisturizer within 3 minutes of bathing while the skin is still slightly damp. This traps moisture and maximizes absorption. Use a generous amount — ideally 4–6 oz per full-body application for an adult. If you’re applying a prescription topical, apply that first on affected areas, then layer moisturizer on top (or wait 30 minutes if you’re using calcineurin inhibitors).

What to avoid: Fragrances, alcohol, formaldehyde-releasing preservatives, and certain surfactants are common irritants and contact allergens in sensitive skin. If you notice a moisturizer consistently worsening your eczema, your dermatologist can arrange patch testing to identify specific allergens. Many people with AD are contact-sensitized to nickel, fragrances, preservatives, or rubber components.

How much is enough? A practical rule: children under 2 go through about 250 g (8 oz) per week; adults with moderate-severe AD may need 500 g or more per week. Buying in large containers significantly reduces cost.

Topical corticosteroids (TCS) have been used for eczema since the 1950s and remain highly effective — but they require proper technique to maximize benefit and minimize risks like skin thinning.

Potency classes (US grouping, 7 classes): Class 1 (strongest, e.g., clobetasol 0.05%) is reserved for thick or severe areas in adults for short courses. Classes 2–4 (mid-strength, e.g., triamcinolone 0.1%, mometasone 0.1%) are workhorses for body eczema. Classes 6–7 (low-potency, e.g., hydrocortisone 1%) are for the face, groin, and underarms, and for infants.

Fingertip unit (FTU): One FTU = the amount of cream squeezed from a standard tube onto the tip of your index finger from fingertip to first crease ≈ 0.5 g. Recommended FTUs per body region: face & neck = 2.5 FTU; one arm = 3 FTU; one hand (both sides) = 1 FTU; chest or back = 7 FTU; one leg = 6 FTU; one foot = 2 FTU.

Wet-wrap therapy: For severe flares, wet wraps dramatically increase TCS penetration and provide cooling itch relief. Apply topical steroid to affected areas, cover with damp (not soaking wet) tubular bandages or cotton garments, then cover with a dry layer. Leave on for 2–6 hours or overnight. Use for short periods (3–5 days max) only under medical supervision because enhanced penetration also increases systemic absorption and potential for skin thinning.

Proactive maintenance therapy: Instead of using TCS only during flares, many guidelines now recommend twice-weekly application to previously-affected areas (even when skin looks clear) to prevent flares from returning. This “proactive” approach reduces the total steroid used over time by preventing frequent flares that require heavier courses.

Steroid phobia is real — and sometimes overtreated: Fear of side effects causes many patients to underuse TCS, leading to prolonged, poorly controlled disease (which itself causes skin damage). The key risk — skin atrophy (thinning, stretch marks, easy bruising) — primarily occurs with long-term use of high-potency steroids on thin-skin areas. With appropriate potency selection and periodic breaks, medium-potency TCS are very safe for body use.

Three newer topical medicines offer effective non-steroidal options, especially useful for areas where you want to minimize steroid exposure or for long-term maintenance.

Crisaborole (Eucrisa) 2% ointment: A phosphodiesterase-4 (PDE4) inhibitor. Works by reducing inflammatory signaling inside skin cells. FDA-approved for mild-to-moderate AD in patients aged ≥3 months. Apply twice daily to affected areas. Takes 4–8 weeks to see full benefit. The main side effect is stinging/burning on application, especially on raw or fissured skin (typically improves as the skin heals). No skin-thinning risk. Less potent than mid-strength TCS but useful for face, eyelids, and long-term maintenance.

Ruxolitinib cream (Opzelura) 1.5%: A topical JAK1/JAK2 inhibitor — the same mechanism as oral JAK inhibitors but with much lower systemic absorption (generally <1% bioavailability when applied to up to 20% BSA). FDA-approved for mild-to-moderate AD in patients aged ≥12 years. Apply twice daily to affected areas. Highly effective for itch relief (often faster than crisaborole). Contains the FDA Boxed Warning for oral JAK inhibitors (same label requirement), though the evidence for cardiovascular and clotting risks at topical doses is very limited. Most providers consider it low-risk for the labeled population (adolescents and adults without high cardiovascular risk) but ask your dermatologist.

Tapinarof 1% cream (Vtama): An aryl hydrocarbon receptor (AhR) agonist — a novel mechanism that reduces Th2/Th17 cytokines and promotes barrier repair. FDA-approved for AD in adults (2024). Applied once daily. In clinical trials, 36–46% of patients achieved treatment success (IGA 0 or 1) at 8 weeks. A unique feature: some patients experience a “remittive effect” where the skin continues to stay clear for weeks even after stopping treatment (median remittive duration ~115 days in trials). Common side effects include folliculitis (around hair follicles) and headache.

Delgocitinib cream (Anzupgo), EU-approved: A topical JAK1/2/3/TYK2 inhibitor approved in the EU/UK for chronic hand eczema in adults. Not yet FDA-approved for general AD but is being studied.

Choosing among non-steroidal options: Your dermatologist will guide you, but generally: for sensitive areas (face, eyelids, genitals) or long-term maintenance, crisaborole or ruxolitinib are options. For itchy localized patches, ruxolitinib tends to be faster. For body AD with some remittive maintenance potential, tapinarof has a unique profile.

Bleach baths (dilute sodium hypochlorite baths) are a low-cost, evidence-supported way to reduce the burden of Staphylococcus aureus on the skin, which is a key trigger for AD flares.

Why they work: In AD, the skin microbiome is disrupted — S. aureus (staph) colonizes the skin in up to 90% of AD patients (compared to ~20% of the general population). Even without an active infection, staph releases toxins called superantigens that directly activate the immune system and worsen inflammation. Reducing staph colonization can dampen this inflammatory trigger.

How to prepare a bleach bath:

Use regular unscented household bleach (sodium hypochlorite, typically 5.25–6% concentration — Clorox regular, not splashless or scented).
For a standard bathtub (~40 gallons / 150 liters): add 1/2 teaspoon per gallon, which equals approximately 1 cup (240 mL) of bleach to a standard tub filled to a comfortable depth. This creates a solution similar in chlorine concentration to a public swimming pool (~0.005%).
Soak for 5–10 minutes, 2–3 times per week.
Do not submerge the head; keep away from eyes. Avoid putting bleach directly on open wounds or very raw skin — if severe, check with your team first.
Rinse with fresh water after, then immediately apply your topical treatments and moisturizer within 3 minutes.

Evidence: Multiple randomized controlled trials show bleach baths reduce AD severity and frequency of skin infections. A 2019 meta-analysis in Annals of Allergy, Asthma & Immunology found significant improvements in EASI and infection rates. They are recommended in EASI and AAD guidelines as an adjunctive measure for recurrent skin infections and flare-prone AD.

Practical tip: If you consistently get worse after a bleach bath, you may have the wrong concentration (try half the amount) or your skin is too raw at that time — start treatment first, then begin baths once the acute flare calms.

Stage 2 — Phototherapy (Light Treatment)

When skin care and topicals aren’t enough but you’re not ready for — or want to avoid — systemic medicines, phototherapy is a well-established option for moderate eczema. The most common form is narrowband ultraviolet B (NB-UVB): controlled doses of a specific wavelength of UV light delivered in a clinic booth, usually two to three times a week for a course of weeks to months.

How it helps. NB-UVB calms the overactive immune response in the skin and can reduce inflammation and itch. It’s steroid-free and doesn’t require blood-test monitoring, which appeals to many people. It can be used alongside moisturizers and (carefully) some topicals.

What to expect

Time commitment is the main downside — repeated clinic visits. Home units exist but need a prescription and supervision.
Short-term effects can include redness (like mild sunburn), dryness, and sometimes itch early on.
Long-term, accumulating a lot of UV exposure over many years can age skin and may slightly raise skin-cancer risk; your clinician weighs this, especially in younger patients and those with many treatments.
Not ideal for everyone — for example, people who can’t make frequent visits, very young children, or those with certain light-sensitive conditions.

Phototherapy often serves as a bridge: it may control disease for a stretch, or buy time while deciding on systemic therapy. For severe, widespread, or fast-moving disease, or when light treatment isn’t practical, your team may move toward biologics or pills (next tab).

Build the schedule into the week early — consistency drives results; missed sessions slow progress.
Keep moisturizing; bring eye protection and follow booth instructions exactly.
Watch for excessive redness or soreness after a session and report it — doses are adjusted individually.
For children, ask whether the burden of frequent visits is worth it versus other options.

Is phototherapy a good fit for my type and severity of eczema?
How many sessions per week, and for how long, before we judge whether it’s working?
What are the short- and long-term risks for me specifically?
Is a home unit an option, and would insurance cover it?
If phototherapy isn’t enough or isn’t practical, what’s the next step?

Phototherapy (light treatment) is an effective step-up from topicals for moderate AD that isn’t controlled by skin care alone — without the systemic side-effect profile of biologics or JAK inhibitors. Here’s what to realistically expect.

Types used for AD: Narrowband UVB (NB-UVB) is the most commonly used — it targets a specific UV wavelength (311–313 nm) that suppresses the Th2 immune response in the skin. Broadband UVB and UVA1 are alternatives; UVA1 penetrates deeper and is particularly useful for thickened, lichenified skin. PUVA (psoralen + UVA) is rarely used for AD today.

Schedule and course length: NB-UVB is typically given 2–3 sessions per week at a dermatology office or phototherapy center. Each session lasts seconds to minutes depending on your skin type and dose titration. A standard course runs 20–40 sessions over 2–4 months. Sessions can’t be skipped freely — there are minimum inter-session intervals for safety, and missed sessions require dose adjustments.

What to expect during treatment: The first sessions are very short (often just 30–60 seconds) and gradually increase. You’ll stand in a light booth (like a standing tanning-bed chamber but calibrated for medical wavelengths) and wear UV-protective goggles. Genitals are shielded. The light can feel warm; some people experience mild sunburn-like pinkness afterward, which should resolve within a day. Excessive redness or blistering means the dose is too high — call your team.

Benefits and when to expect them: Most people begin to see improvement after 15–20 sessions, with best results after completing the full course. In responders, significant itch reduction and skin clearing are common. Benefits often last several months after stopping. Repeat courses are possible and effective.

Practical considerations: The biggest challenge is time commitment — 2–3 office visits per week for months. This is why home NB-UVB units exist; they require a prescription, upfront cost (~$1,500–$3,000), and training, but eliminate travel. Some insurance covers home units after documented office treatment. For people with limited geographic access to phototherapy facilities, home units can be life-changing. The National Eczema Association can help identify covered options.

Long-term safety: Cumulative UV exposure increases skin aging and, over many years of repeated courses, marginally increases skin cancer risk (though less so than outdoor sun exposure). People with a history of skin cancers should discuss with their dermatologist. Oral medications (doxycycline, certain antibiotics, diuretics) can increase photosensitivity — review your full medication list with your team before starting.

Stage 3 — Biologic Injections & Oral JAK Pills (for Moderate-to-Severe Disease)

For eczema that’s moderate-to-severe and not controlled by skin care, topicals, and (where appropriate) phototherapy, modern systemic treatments are often life-changing. They fall into two main groups: targeted biologic injections and oral JAK-inhibitor pills. There are also older systemic medicines used in some situations.

Biologic injections: precise, well-tolerated, no routine blood tests

Biologics are antibodies given by injection under the skin (often a pre-filled pen) on a schedule (e.g., every 2 or 4 weeks). They block specific immune signals driving eczema. They generally do not require routine lab monitoring, and they are not broad immune suppressants.

Dupilumab blocks IL-4 and IL-13 signaling. It’s the first and most established eczema biologic, approved across ages down to 6 months. Many people see major skin clearing and itch relief. The most notable side effect is eye irritation/conjunctivitis (red, itchy, gritty eyes) in a minority of users, usually manageable; some develop redness on the face/neck. No routine blood tests needed.
Tralokinumab and lebrikizumab block IL-13. Lebrikizumab is approved for ages 12+ (and at least ~40 kg). Tralokinumab is approved for adults and adolescents. Like dupilumab, they can cause some conjunctivitis but at generally lower rates.
Nemolizumab blocks the IL-31 receptor — the main “itch” signal. It’s approved for ages 12+ with moderate-to-severe AD, used together with topical steroids and/or calcineurin inhibitors. It’s especially relevant when itch is the dominant, most distressing problem (it’s also approved for a related itchy condition, prurigo nodularis). Itch and sleep can improve within days.

Eye side effects. If you notice red, itchy, watery, or gritty eyes on dupilumab or another IL-13–targeting biologic, tell your team — don’t just stop. Lubricating drops, anti-inflammatory eye drops, or an eye-doctor referral usually manage it, and most people continue treatment successfully.

Oral JAK-inhibitor pills: fast and effective — with serious warnings

JAK inhibitors are daily pills that block several itch/inflammation signals at once. They work quickly (itch can ease within days) and can produce high levels of skin clearing.

Upadacitinib and abrocitinib are approved for moderate-to-severe AD (generally ages 12+) when other systemic treatments haven’t worked or aren’t advisable.
They carry a boxed warning — the FDA’s most serious — covering risks of serious infections, blood clots, major heart events (heart attack/stroke), cancer, and death. This warning is shared across the JAK-inhibitor class and is based largely on a study in older rheumatoid-arthritis patients with heart-disease risk factors.
Because of this, your clinician will screen before starting (e.g., for tuberculosis and hepatitis, plus blood counts and cholesterol) and monitor on treatment, and will weigh your personal risk factors (age over 65, smoking, history of clots, heart disease, or cancer).

Understanding the JAK warning without fear or denial. For a younger person without heart-disease or clotting risk factors, the absolute risk appears low, and the rapid relief can be worth it. For an older person or someone with risk factors, biologics are often preferred first. This is exactly the kind of personalized, shared decision you should make with your clinician — not alone, and not based on internet fear.

Older (“conventional”) systemic medicines

Before biologics and JAK inhibitors, doctors used broad immune-suppressing medicines: cyclosporine (fast but limited to shorter-term use), methotrexate, azathioprine, and mycophenolate. They still have a role — especially where newer drugs aren’t available, affordable, or suitable — but they require regular blood-test monitoring and have their own risks. Your team will explain monitoring if one is chosen.

There’s no single “right” order, but a common pattern is: optimize skin care + topicals → add phototherapy and/or a systemic treatment for moderate-to-severe disease → for most people, a biologic (often dupilumab) is a strong first systemic choice because of its safety profile and no-routine-labs convenience → an oral JAK inhibitor may be chosen for very fast relief, pill preference, or when biologics haven’t worked, balancing the boxed-warning risks. Once you’re well controlled, your team may discuss carefully stepping down treatment. The best first choice depends on your severity, itch burden, age, other health conditions, preferences, and access.

Injections: learn the technique from the nurse/pharmacist; keep pens refrigerated; set calendar reminders; rotate injection sites; have a sharps container.
Pills (JAK): support a daily routine, keep lab appointments, and know the warning signs to report promptly (fever or signs of infection, leg swelling/pain or chest pain/shortness of breath, new lumps or changing skin spots).
Eyes on biologics: watch for red/itchy eyes and report them; they’re usually treatable.
Don’t stop abruptly without talking to the team — eczema can rebound.
Specialty pharmacy & cost: these drugs are expensive; ask about prior authorization help and manufacturer patient-assistance programs.

Am I a candidate for a biologic, and which one fits my situation (including my age and whether itch is my biggest problem)?
What should I expect from a biologic, and how soon — including the chance of eye side effects?
Would an oral JAK inhibitor be reasonable for me, and what do its boxed warnings mean given my health and age?
What screening and ongoing monitoring will I need on a JAK inhibitor?
How do we decide between a biologic and a pill?
Are conventional systemics (cyclosporine, methotrexate, azathioprine, mycophenolate) relevant for me, and why or why not?
What’s the plan if the first systemic treatment doesn’t work well enough?
Once I’m clear, can we discuss stepping down treatment safely?
Can your team help with insurance approval and patient-assistance programs?

Dupilumab (Dupixent) is the most prescribed biologic for AD worldwide, and most people find it manageable once they get comfortable with the injections. Here’s a practical guide.

How it’s given: Dupilumab comes in a pre-filled syringe or auto-injector pen. Adults start with a 600 mg loading dose (two 300 mg injections on the same day), then 300 mg every 2 weeks. For children and adolescents, the dosing is weight-based. Injections go into the thigh or abdomen (rotate sites); you or a caregiver give them at home after your first clinical injection.

Getting comfortable with self-injection: Most people feel anxious before their first injection. Tips: let the pen warm to room temperature for 30 minutes before injecting (reduces stinging); inject slowly; try numbing the area with an ice cube for 30 seconds first; exhale as you inject. The needle is very fine and the discomfort is typically brief. Your pharmacist or nurse can walk you through technique.

What to expect in the first weeks:

Weeks 1–4: Itch often improves first, sometimes dramatically in the first 2 weeks. Skin may take longer to visibly clear.
Weeks 4–16: Most skin improvement occurs in this window. By week 16, the majority of responders have reached substantial or near-complete clearance.
Months 4+: Continued slow improvement in some patients. Some achieve complete clearance; others maintain very well-controlled, low-activity disease.

Eye side effects (conjunctivitis): About 10–20% of adults on dupilumab develop some degree of eye irritation — red, gritty, itchy, watery eyes. This is more common in patients with pre-existing eye inflammation. Do not stop dupilumab because of this without talking to your team first — most cases are manageable. Options include preservative-free lubricating drops, over-the-counter antihistamine eye drops, or, for persistent cases, ophthalmologist-prescribed anti-inflammatory eye drops (e.g., cyclosporine or steroid drops for short-term use). Switching to a pure IL-13 blocker (tralokinumab or lebrikizumab) has lower conjunctivitis rates if this is a persistent problem.

Head, neck, and face redness: Some people notice new or worsened redness on the face, neck, and scalp when starting dupilumab. This is thought to be partly related to Malassezia (a skin yeast) overgrowth or a change in the skin immune environment. It’s usually manageable with topical antifungals, anti-inflammatories, or adjusting how you use topicals in these areas. A dermatologist can help sort this out.

Oral JAK inhibitors (upadacitinib/Rinvoq, abrocitinib/Cibinqo, baricitinib/Olumiant) are highly effective pills taken once daily. Their fast action — itch can improve significantly within the first week — is one of their biggest advantages for people with severe disease who need rapid relief.

Starting a JAK inhibitor: Before starting, your doctor will order baseline labs including a complete blood count (CBC), liver function tests (LFTs), lipid panel, and test for latent tuberculosis (TB screening). A test for hepatitis B is also standard. These are not optional — JAK inhibitors can rarely cause serious infections including reactivation of latent infections, so your baseline health status needs to be known.

Day-to-day experience:

Upadacitinib (Rinvoq): Usually 15 mg once daily for AD; 30 mg in severe cases. Taken at the same time daily, with or without food. Most people notice itch relief within days and significant skin clearing by 2–4 weeks. Available for patients aged 6 and older.
Abrocitinib (Cibinqo): 100 mg or 200 mg once daily. Can cause mild nausea in the first few weeks (often improves; taking with food helps). Also notable for itch relief within days. For 12+ years.
Baricitinib (Olumiant): 2 mg or 4 mg once daily. The longest safety follow-up data of the three. Approved for adults with moderate-to-severe AD.

Ongoing monitoring: CBC, LFTs, and lipids are rechecked periodically (typically at 3 months, then every 3–6 months). Your platelet count and absolute lymphocyte count are monitored because JAK inhibitors can occasionally reduce these. If your absolute lymphocyte count drops significantly, your dose may be reduced or paused.

Vaccinations: Because JAK inhibitors reduce immune function, you should ideally be up-to-date with key vaccinations before starting. Particularly important: herpes zoster vaccine (Shingrix) — JAK inhibitors increase the risk of shingles (herpes zoster), and Shingrix is highly effective at preventing it. It’s recommended for adults starting a JAK inhibitor regardless of age. Live vaccines (MMR, varicella, yellow fever) are generally avoided while on JAK inhibitors — get them before starting if needed.

All oral JAK inhibitors carry a Boxed Warning — the FDA’s strongest warning — for serious risks including serious infections, major adverse cardiovascular events (heart attack, stroke), blood clots (venous thromboembolism/VTE), cancer, and death. This sounds alarming, but the context matters enormously for understanding your personal risk.

Where did this warning come from? The primary safety data driving this warning came from a trial called ORAL Surveillance, which studied tofacitinib (a JAK inhibitor for rheumatoid arthritis) in older patients with RA who had additional cardiovascular risk factors — compared to TNF-blocker biologics. In that population, tofacitinib was associated with higher rates of MACE, VTE, and malignancy. The FDA then applied similar warnings to all JAK inhibitors across all conditions.

Why the AD situation is different:

Patient profile: Most AD patients starting JAK inhibitors are younger adults and teenagers, without the cardiovascular risk factors, smoking history, and pre-existing heart disease of the RA patients in ORAL Surveillance.
Disease context: RA itself has high baseline cardiovascular risk; AD does not have the same underlying cardiovascular burden.
Real-world AD data: Ongoing post-market AD-specific safety studies show markedly lower rates of MACE and VTE in AD patients on JAK inhibitors than in the ORAL Surveillance RA cohort.

Who should be most cautious: Patients over 65, those who smoke or have smoked, anyone with prior heart disease, heart failure, stroke, or known clotting disorders should have a detailed discussion with their doctor about whether a JAK inhibitor is appropriate. For many such patients, a biologic injection (which does not carry these warnings) may be preferred.

The bottom line: For a healthy 25-year-old with severe eczema and no cardiovascular risk factors, the absolute risk from a JAK inhibitor is very low. For a 60-year-old with prior heart disease and hypertension, the risk-benefit balance is different. Your doctor will review your personal risk factors with you. The boxed warning means “consider carefully” — not “never use.”

Dupilumab, other biologics, and JAK inhibitors are expensive — often $30,000–$45,000 per year at list price. Most patients do not pay this. Here’s how to navigate coverage and assistance.

Insurance prior authorization (PA): Virtually all insurers require PA before approving a biologic or JAK inhibitor for AD. Requirements typically include documented moderate-to-severe disease (IGA ≥3 or EASI ≥16), and failure or contraindication to at least one conventional systemic therapy (such as cyclosporine or methotrexate) or phototherapy. Your dermatologist’s office submits the PA; the process takes 2–4 weeks. If denied, you have the right to appeal — your doctor’s office can submit a letter of medical necessity.

Manufacturer patient assistance programs:

Dupixent MyWay (dupilumab): 1-844-DUPIXENT (1-844-387-4936). Co-pay assistance for commercially insured patients (co-pay as low as $0/month for eligible patients); free drug program for uninsured/underinsured who meet income criteria. myway.dupixent.com
AbbVie myAbbVie Assist (upadacitinib/Rinvoq): 1-800-2ASSIST (1-800-222-7748). Similar co-pay and free drug programs. myabbvieassist.com
Pfizer RxPathways (abrocitinib/Cibinqo): 1-800-645-1280. rxpathways.com
Eli Lilly Cares Foundation (baricitinib/Olumiant, lebrikizumab/Ebglyss): 1-800-545-5979. lillycares.com
LEO Pharma (tralokinumab/Adbry): 1-833-MY-ADBRY. Contact through adbryhcp.com
Galderma (nemolizumab/Nemluvio): Contact galderma.com for patient support programs.

Independent foundations: The Patient Advocate Foundation (patientadvocate.org) and the HealthWell Foundation (healthwellfoundation.org) offer co-pay and premium assistance programs for patients who don’t qualify for manufacturer programs or have gaps in coverage. The National Eczema Association (nationaleczema.org) maintains an updated list of AD-specific financial assistance resources.

Biosimilars: Dupilumab is protected by patents until approximately 2036 in the US (though litigation may change this). Multiple biosimilar applications are in development (SB17/Samsung Bioepis, HD204/Hadassah); none are approved in the US yet. When biosimilars become available, they will likely reduce costs significantly.

Stage 4 — Managing Itch, Sleep, and Skin Infections

Itch is usually the single most distressing part of eczema, and it wrecks sleep, which in turn worsens mood, focus, and the eczema itself. Skin infections are common and occasionally dangerous. This section is about comfort and safety.

It helps to understand why the itch of eczema is so relentless, because it changes how you treat it. In atopic dermatitis, the itch isn't just from dryness — the inflammation in the skin releases signals that directly switch on itch nerves, and over time those nerves become sensitized, so the skin itches more easily and more intensely (a state doctors call the “itch-scratch cycle”). Scratching feels good for a moment but damages the skin barrier and releases more inflammation, which causes more itch — a self-feeding loop. This is the key insight behind modern treatment: because the itch is driven by inflammation and overactive itch nerves, the most effective way to control it is to treat the underlying inflammation (with your topical or, for more severe disease, systemic medicines) rather than relying on antihistamines, which often don't help eczema itch much. The newer biologic and JAK treatments work partly because they calm exactly these itch signals, and many people notice the itch ease before the rash fully clears. In the meantime, keeping skin well-moisturized, using cool compresses, keeping nails short, and managing stress and overheating (both can trigger itch) all help take the edge off and protect the skin while the medicines do the deeper work.

A note on triggers and flares, because identifying and reducing your personal triggers is a powerful, no-cost part of control. Common ones include harsh soaps and detergents, very hot water and long showers, dry or cold air (and the sweat and heat of summer for some), rough fabrics like wool, stress, and — for some people — specific allergens. Not everyone has the same triggers, and chasing food allergies is usually not helpful for most adults and children with eczema (restrictive diets can do more harm than good and should only be pursued with medical guidance). The practical approach is to notice what tends to precede your flares, reduce those exposures where you reasonably can, and keep up your daily moisturizing and maintenance treatment even when the skin looks clear — because consistent “baseline” care prevents flares far better than only reacting once the skin is bad. Think of eczema as a long-term condition you manage rather than a problem you fix once: steady daily care plus prompt treatment of flares keeps most people comfortable and in control.

Breaking the itch-scratch cycle

Treat the inflammation — the most effective “anti-itch” step is controlling the eczema with topicals or, when needed, systemic treatment. Nemolizumab and oral JAK inhibitors target itch directly and fast.
Cool the skin: cool compresses, keeping rooms cool, lightweight breathable cotton clothing.
Moisturize — well-hydrated skin itches less.
Reduce scratch damage: short, smooth nails; soft mittens or cotton gloves at night for children; gentle pressure or tapping instead of scratching.
Distraction and habit-reversal techniques help break automatic scratching.
Antihistamines don’t treat eczema itch well; a sedating one at night may aid sleep short-term, but it’s not a real solution. Talk to your clinician.

Sleep

Don’t treat poor sleep as inevitable. Better eczema control is the best sleep aid. A cool bedroom, an evening soak-and-seal routine, soft bedding, and itch-targeted treatment (nemolizumab, JAK inhibitors) can restore nights. Persistent sleep loss is itself a reason to escalate treatment — tell your team.

Skin infections: recognize and treat promptly

Broken eczema skin is prone to infection.

Bacterial (often Staph) infection: increasing redness, weeping, honey-colored crusting, pain, pus, or a flare that suddenly worsens and won’t respond to usual care. This needs prompt medical review and sometimes antibiotics. Your clinician may also suggest diluted bleach baths for some people with recurrent infections (done with guidance).

⚠ Eczema herpeticum — a true emergency. If eczema skin develops painful clusters of small blisters or “punched-out” sores that spread quickly, especially with fever, swollen glands, or feeling generally unwell, this can be a herpes-virus infection of eczema skin called eczema herpeticum. Seek same-day/urgent medical care. It needs prompt antiviral treatment and can be serious, particularly in children. Don’t wait it out and don’t just apply more steroid.

One more red flag. If you’ve been using a topical calcineurin inhibitor (tacrolimus/pimecrolimus) and develop a spreading blistering rash, stop and get reviewed — rarely these can be involved when herpes infection spreads.

Keep nails trimmed; consider cotton mittens at night for young children.
Have cool compresses ready; keep the bedroom cool and use breathable bedding.
Learn the look of honey-colored crusting (bacterial) and clustered painful blisters + fever (eczema herpeticum — urgent).
Take a photo when something looks “off” so you can show the clinician and track change.
If sleep is repeatedly destroyed by itch, push for stronger eczema control — it’s a legitimate reason to escalate.

What’s my best plan to break the itch-scratch cycle?
Given how much itch and poor sleep affect me, should we consider an itch-targeted treatment (nemolizumab or a JAK inhibitor)?
How do I tell a normal flare from a bacterial infection? When do I need antibiotics?
Are diluted bleach baths appropriate for me, and how do I do them safely?
What exactly does eczema herpeticum look like, and where do I go if I suspect it after hours?
Are antihistamines worth using for me, and which kind?

Itch in AD is not the same as the incidental itching from a mosquito bite. It operates through nerve fibers sensitized by the same inflammatory cytokines (particularly IL-31, TSLP, and IL-33) that drive skin inflammation. This is why controlling inflammation is the most powerful anti-itch strategy — and why antihistamines (which block histamine but not these pathways) are largely ineffective for chronic AD itch.

First-line itch strategies:

Treat the underlying inflammation: Get your eczema into remission or low-activity state. A well-controlled disease is a low-itch disease. Biologics and JAK inhibitors often eliminate itch that topicals couldn’t reach.
Cool the skin: Cold water, wet towels, or ice packs applied briefly to itchy areas interrupt the itch-scratch cycle. Keep the bedroom cool at night if possible.
Moisturize frequently: Dry skin amplifies itch. Multiple applications per day (including in the middle of the night if you wake itching) help.
Distraction techniques: Rubbing or pressing on itchy areas (instead of scratching) stimulates different nerve fibers and can partially satisfy the itch urge without damaging the skin barrier.
Habit reversal training (HRT): A behavioral therapy where a trained therapist helps you recognize and interrupt scratching behaviors, replacing them with a competing response. Evidence shows it reduces scratching and skin damage. Worth asking about if scratching is a major problem even when itch is controlled.

Antihistamines in AD: Oral antihistamines block histamine receptors but histamine is not the primary mediator of AD itch. Randomized trials show non-sedating antihistamines (cetirizine, loratadine, fexofenadine) are generally not effective for AD itch. Sedating antihistamines (hydroxyzine, diphenhydramine) can help at night — not because they reduce itch but because their sedating effect helps you sleep through it. Use cautiously and not long-term due to tolerance and cognitive effects.

Nemolizumab for itch-dominant disease: If your itch is disproportionately severe relative to your visible skin disease, nemolizumab (Nemluvio) — which directly blocks the IL-31 receptor — may be a consideration. In trials, itch began improving significantly within the first week. It is FDA-approved for ages 12+ and is used alongside topical steroids or calcineurin inhibitors.

Sleep disruption is one of the most damaging aspects of moderate-to-severe AD. Studies consistently show that people with active eczema scratch dozens to hundreds of times per night during sleep without being aware of it. This nocturnal scratching perpetuates skin damage and prevents healing. Meanwhile, poor sleep worsens immune regulation, which can worsen eczema — creating a bidirectional cycle.

Environmental strategies:

Bedroom temperature: Keep the bedroom cool (65–68°F / 18–20°C). Heat dramatically worsens itch. Use breathable cotton or bamboo bedding; avoid synthetic fabrics and wool directly against the skin.
Dust mite reduction: If house dust mites are a trigger (positive allergy test or clinical suspicion), use allergen-proof mattress and pillow covers, wash bedding weekly in hot water (≥60°C / 140°F), and reduce carpeting where possible. HEPA air purifiers may help in high-mite environments.
Evening skin care routine: A thorough topical routine before bed (moisturizer + any prescribed topicals) reduces the overnight itch burden. Long-sleeved cotton pyjamas create a physical barrier against scratching.
Cotton gloves or mittens: Wearing soft cotton gloves overnight prevents damage from unconscious scratching, especially for children who scratch heavily in sleep.

Medications that help with sleep: Low-dose doxepin (a tricyclic with antihistamine and sedative properties) is sometimes used specifically for nocturnal itch in AD. Hydroxyzine can help with sleep onset, though tolerance develops. Melatonin has some evidence in pediatric AD. For adults with severe, sleep-disrupting disease, addressing the underlying inflammation with systemic treatment is more effective than sleep medications alone — many people’s sleep normalizes dramatically once their AD is well-controlled.

CBT-I (Cognitive Behavioral Therapy for Insomnia): If insomnia persists even after AD is controlled, CBT-I is highly effective for conditioning good sleep habits. It’s available through apps (Sleepio, Somryst), online programs, or a therapist, and is more effective than sleep medications long-term.

AD skin is much more prone to infection than healthy skin, both because the barrier is compromised and because the immune environment is shifted. Three types of infection are particularly important to recognize.

1. Bacterial infection (usually Staphylococcus aureus): Signs of active bacterial infection (beyond colonization) include honey-colored crusting, oozing/weeping pus, rapidly worsening or non-healing areas, warm/red/swollen skin, and sometimes fever. Mild impetigo can be treated with topical mupirocin (Bactroban) or retapamulin. More extensive infections need oral antibiotics — cephalexin or dicloxacillin for MSSA; trimethoprim-sulfamethoxazole (TMP-SMX) or clindamycin if MRSA is suspected (especially in geographic areas with high MRSA rates or if prior MRSA). Crucially: antibiotics should NOT be used for staph colonization without clinical infection — this promotes antibiotic resistance and doesn’t improve AD long-term.

2. Eczema herpeticum (viral emergency): This is a potentially serious infection caused by the herpes simplex virus (HSV) spreading over eczematous skin. Signs are distinctive: clusters of uniform, punched-out small blisters (often 1–3 mm), that can rapidly spread across large areas. The blisters may break open leaving shallow ulcerations with crusting. The distribution often looks different from typical eczema flares — it crosses normal-skin areas and can involve the face, around the eyes, and widespread body areas. There may be fever, swollen lymph nodes, and feeling very unwell. If you suspect eczema herpeticum, seek urgent medical attention the same day — it requires antiviral treatment (oral or IV acyclovir) and can be dangerous if delayed. It looks alarming but responds well to prompt treatment.

3. Fungal infections: Tinea (ringworm) and Candida can superimpose on eczematous skin. Malassezia (a skin yeast) is associated with head/neck/face AD and may worsen it; antifungal shampoos or topicals (ketoconazole, selenium sulfide) are sometimes used as part of management in these patterns. Ask your dermatologist if your face/scalp/neck disease is disproportionately active.

Preventing infection: Bleach baths (see above), daily moisturizing to maintain barrier function, avoiding prolonged dampness (e.g., wet swimwear), and trimming fingernails short to reduce bacteria under nails all help reduce infection frequency. If you have recurrent infections (3 or more per year), your dermatologist may recommend ongoing prophylactic bleach baths or periodic topical antibiotic courses.

Stage 5 — Eczema in Children, the Atopic March, and Living Well

Eczema in babies and children

Childhood eczema is very common and very treatable. The same foundation applies — generous moisturizer, gentle bathing, and appropriate topical anti-inflammatories using the fingertip-unit guide. For moderate-to-severe childhood eczema not controlled by topicals, dupilumab is approved down to 6 months of age, and several topicals (crisaborole from 3 months; roflumilast from age 2; tapinarof from age 2) widen steroid-free options. Uncontrolled eczema can disrupt a child’s sleep, growth, learning, and confidence, so don’t accept “they’ll grow out of it” as a reason to undertreat.

Food and eczema in children. Most childhood eczema is not caused by food. Avoid broad elimination diets unless directed by an allergist — unnecessary restriction can harm nutrition and may actually increase the risk of developing food allergy. If you suspect a food trigger or your child has had an allergic reaction, ask for proper allergy evaluation.

The atopic march

Eczema is often the first step in the “atopic march” — a tendency for some children to go on to develop food allergy, asthma, and hay fever (allergic rhinitis), and sometimes a swallowing condition called eosinophilic esophagitis. Not every child marches, but it’s why your team may ask about wheezing, nasal symptoms, and feeding. Research is testing whether early, intensive skin-barrier care or other early steps can prevent eczema or the march in high-risk infants — promising but not yet proven enough to be standard.

Mental health and the emotional toll

Eczema can carry real psychological weight: embarrassment, sleep loss, anxiety, depression, and social stigma — in both children and adults. This is not vanity; it’s part of the disease burden, and it’s a valid reason to treat more assertively. Tell your clinician if eczema is affecting your mood, relationships, or daily functioning. Support, counseling, and better disease control all help.

School, work, and daily life

School/daycare: share a simple written care plan so staff can help with moisturizer and avoid blame for scratching; address bullying directly.
Clothing: soft, breathable cotton; avoid wool and rough seams; manage sweat and overheating.
Activities/sports: rinse off sweat and chlorine and re-moisturize afterward; don’t let eczema stop participation.

Pregnancy and breastfeeding

Eczema can change during pregnancy. Many topical treatments and some systemic options are used in pregnancy under guidance. Among biologics, dupilumab has the most accumulated reassurance and is sometimes continued in pregnancy after individualized discussion, while oral JAK inhibitors are generally avoided in pregnancy. Always plan ahead with your clinician (and obstetrician) — don’t stop or start treatment on your own.

Make skin care a calm, predictable routine, not a battle — pair it with stories, music, or rewards.
Provide a written plan to school/daycare; pre-position moisturizer there.
Watch for — and name — the emotional toll; loop in counselors if a child is withdrawn, anxious, or bullied.
Keep dermatology and allergy appointments; ask whether asthma/allergy screening is warranted.
Care for the caregiver too: nighttime scratching and disrupted sleep are exhausting; ask for help.

What’s the safest, most effective plan for my child’s age — and when would a biologic like dupilumab be appropriate?
Should we screen for or watch for asthma, hay fever, or food allergy (the atopic march)?
Do we need allergy testing, or could food elimination do more harm than good?
How is eczema affecting sleep, growth, school, or mood — and should that change our treatment?
Which treatments are safe in pregnancy or while breastfeeding, and how do we plan around a pregnancy?
Can you help me write a school/daycare care plan?

The “atopic march” refers to the tendency in some individuals with early-onset AD to develop additional allergic conditions over time — typically food allergy first, then asthma, then allergic rhinitis — in that sequence. Understanding this concept helps families make informed decisions, but it also carries significant misconceptions.

What we know: Children with moderate-to-severe AD have a substantially higher risk of developing food allergy (particularly to peanut, egg, and milk) and asthma than children without AD. The AD-driven skin barrier disruption is thought to allow food proteins to enter through the skin, triggering sensitization before the child is orally exposed. This is the basis for the epidemiological observation that AD often precedes food allergy.

What the march doesn’t mean:

It is NOT inevitable — many children with AD never develop asthma or food allergy.
It is NOT caused by food exposure through eating — it’s caused by percutaneous (through-the-skin) sensitization. This is why avoiding foods in the diet does NOT prevent sensitization and may actually increase allergy risk. The LEAP trial (Learning Early About Peanut Allergy) showed that early oral introduction of peanut to high-risk infants (those with severe eczema) reduced peanut allergy by 80%.
Dietary elimination diets for AD are not proven to treat AD or prevent the march in most patients and risk nutritional deficiencies, especially in young children. Only pursue food elimination after positive allergy testing in consultation with an allergist-immunologist.

What to do: For infants and children with moderate-to-severe AD, early consultation with a pediatric allergist-immunologist is valuable for (1) assessing food allergy risk and guiding safe early introduction of foods, (2) testing for aeroallergen sensitization, and (3) discussing asthma prevention strategies. Early, aggressive AD treatment to restore the skin barrier may also reduce percutaneous sensitization — this is an active area of research. The ProAD study (prophylactic emollient use from birth in high-risk infants) showed modest barrier benefit; ongoing trials test whether early dupilumab might interrupt the march.

AD affects far more than skin. Research consistently shows that moderate-to-severe AD has quality-of-life impacts comparable to psoriasis, rheumatoid arthritis, and other chronic conditions. Taking the non-skin aspects of eczema as seriously as the dermatologic ones is part of comprehensive care.

Mental health: Anxiety and depression are significantly more common in people with AD than in the general population. The relationship is bidirectional: stress can worsen eczema (through neuroimmune pathways involving cortisol and mast cells), and eczema causes stress. If you notice persistent low mood, anxiety, or social withdrawal related to your skin, bring it up with your dermatologist — not just your primary care provider. Many academic dermatology practices now have integrated behavioral health. Cognitive-behavioral therapy (CBT) for chronic illness specifically targeting the AD experience is available and effective.

Work and daily activities: Certain occupational exposures are strong AD triggers: healthcare workers (wet work, frequent handwashing, latex gloves), hairdressers and cleaners (detergents, dyes), and food service workers (wet work, flour, citrus). If you’re choosing a career, this is worth factoring in. If you’re already in an AD-aggravating occupation, discuss with an occupational health or dermatology specialist — protective barrier creams, glove protocols, and clinical management can often make it workable.

Exercise and swimming: Exercise and its associated sweating can transiently worsen AD itch. Strategies: shower immediately after exercise; use a cool shower to remove sweat; reapply moisturizer within 3 minutes. Swimming in chlorinated pools can be both drying and sensitizing for some; rinsing off immediately after and applying moisturizer helps. Some patients with AD find swimming actually helps their skin (especially if they have fungal/bacterial colonization — the pool chlorine acting like a bleach bath). Experiment and note what works for you.

Diet: There is no well-proven anti-eczema diet. The evidence for elimination diets in the absence of confirmed food allergy is very weak — and nutritional restriction in children can cause more harm than good. Broad patterns that support overall immune health (Mediterranean diet: olive oil, vegetables, fish, legumes, nuts; limited ultra-processed foods) are reasonable lifestyle choices but shouldn’t be expected to replace medical treatment. If you suspect a specific food triggers flares, work with a dietitian and allergist to test this systematically rather than self-restricting.

Relationships and intimacy: AD affects self-esteem and physical intimacy for many people. Sleep disruption affects partners. Open communication with partners and loved ones about the condition — including that it is not contagious — and seeking support from the eczema community (National Eczema Association online forums, peer support) can significantly reduce the psychosocial burden.

Managing atopic dermatitis in children extends beyond skin care routines into the daily environments where children spend most of their time. School and daycare staff, coaches, and even other children's parents may not understand AD — and preparing those environments proactively reduces both flare risk and social stigma.

Talking to the school: Children with moderate-to-severe AD may need formal accommodations under Section 504 or an Individualized Education Program (IEP) if the disease significantly affects their learning (from sleep disruption or itch distraction in class). Most schools are willing to accommodate: keeping a moisturizer in the nurse's office for application during the day, a note from the dermatologist asking that the child not be penalized for scratching, allowance for extra bathroom breaks to rinse and reapply cream, and permission to wear long sleeves or gloves on cold days without it being a dress code issue. Many state health departments have AD school accommodation letter templates; your dermatologist can complete one.

Gym class, swimming, and sports: Chlorine can flare AD but is also somewhat antimicrobial; immediate post-swim rinsing and moisturizing prevents most chlorine-related flares. Sweating during gym class triggers itch — having the child rinse their face with cool water after exercise and reapply emollient helps. Synthetic moisture-wicking sportswear reduces sweat retention against the skin. For contact sports, equipment padding rubbing against sensitive skin may need fabric barrier liners. Most children can participate fully in sports with appropriate preparation; exclusion is rarely medically necessary.

Managing itch in the classroom: Itch during class disrupts concentration and triggers scratching that damages the skin further. Strategies: keeping the classroom cool (heat worsens itch), having a fidget tool to redirect scratch impulses, and discussing with the teacher that visible scratching is involuntary rather than disruptive. The NRS (Numerical Rating Scale for itch) can be useful for older children (age 7+) to self-report itch severity — some teachers find it helpful for monitoring when a child is having a particularly bad day.

Explaining AD to other children: Children with AD often face questions about visible rash, especially on exposed skin. Age-appropriate explanations: "My skin is extra sensitive and sometimes gets irritated" works for younger children. For older children: "I have a skin condition called eczema — it's not contagious and it doesn't hurt to be near me." Role-playing responses with parents at home prepares children for these situations. The National Eczema Association (nationaleczema.org) has free downloadable school accommodation letters and age-appropriate materials for teachers and peers.

Questions to ask your child's care team:

Does my child need a formal 504 accommodation plan for school?
How do I handle a classmate's parent who is worried about contagion?
At what severity level should I keep my child home from school during a flare?
Are there summer camps specifically for children with eczema or allergies?

Support & Resources

Clinical Trials — how to find them and what’s out there

Eczema research is highly active worldwide, and trials are reasonable to ask about in any region. The therapies described in this guide were proven in large trials; new ones aim for longer-lasting control, easier dosing, and better itch relief. To search:

Go to ClinicalTrials.gov and search “atopic dermatitis” (filter by recruiting status and your location).
Internationally: the WHO ICTRP portal, the EU CTIS register, Japan’s jRCT, and others list regional trials.
The National Eczema Association offers trial information and patient resources.
Ask your dermatologist whether an academic center near you (e.g., University of Utah) is enrolling.

Examples of the kinds of programs that built today’s treatments (for reference; verify current status before assuming enrollment): dupilumab’s LIBERTY AD trials including SOLO 1/2 (NCT02277743, NCT02277769), CHRONOS (NCT02260986), and pediatric/infant studies (NCT03345914, NCT03346434); tralokinumab’s ECZTRA trials (NCT03131648, NCT03160885, NCT03363854); lebrikizumab’s ADvocate1/2 and ADhere (NCT04146363, NCT04178967, NCT04250337); nemolizumab’s ARCADIA 1/2 (NCT03985943, NCT03989349); upadacitinib’s Measure Up 1/2, AD Up, and Heads Up (NCT03569293, NCT03607422, NCT03568318, NCT03738397); and abrocitinib’s JADE program (NCT03349060, NCT03575871, NCT03720470, NCT03796676). Newer agents aimed at upstream signals (such as TSLP and OX40/OX40L) are in trials now.

Failed or De-adopted Therapies — honest answers to claims you’ll see online

Patients encounter many claims. Here’s what rigorous evidence shows doesn’t reliably work for eczema itself:

Antihistamines as an eczema treatment. They don’t control the underlying inflammation or chronic itch; a sedating one may help sleep short-term, but they’re not a core therapy.
Broad food-elimination diets. For most people they don’t improve eczema and can cause harm (poor nutrition; new food allergies in children). Pursue only with allergist guidance.
Oral corticosteroids for long-term control. Repeated or long courses cause significant harm and rebound flares; reserved, if ever, for short rescue.
Routine systemic antibiotics for non-infected eczema. Don’t help and drive resistance; antibiotics are for genuine infection.
“Detox,” most supplements, and unproven natural cures. Evidence-based reviews have not shown reliable benefit for evening primrose oil or borage oil, and probiotics and vitamin/mineral supplements have not been shown to treat established eczema. They are not substitutes for proven care, and some herbal/“natural” products are contaminated with hidden steroids or interact with medicines.
“Topical steroid addiction/withdrawal” framing. Steroid overuse can cause skin problems, but the online narrative often leads people to abandon effective treatment. Discuss real concerns with your clinician rather than stopping all topicals.

About supplements and herbal products. If you’re considering any supplement or herbal/traditional remedy, tell your clinician and pharmacist first. “Natural” does not mean safe or inert: products can be contaminated (including with undisclosed corticosteroids), and some interact with immune-affecting medicines. No supplement is a proven substitute for standard eczema care. (Note: a dedicated herb–drug interaction database was not reachable while preparing this guide; your pharmacist can check interactions for your specific medicines.)

International Access & Regulatory Landscape

The foundation of eczema care — barrier care and topicals — is recommended worldwide and is the global mainstay. Access to biologics and JAK inhibitors varies widely by country and insurance, and approval timing differs by region:

Therapy	US (FDA)	Europe (EMA)	Japan (PMDA)	Notes
Dupilumab (IL-4/13)	Approved, from 6 months	Approved	Approved	Most established; widest age range
Tralokinumab (IL-13)	Approved (adults + 12+)	Approved	Approved	Brand names differ by region
Lebrikizumab (IL-13)	Approved Sept 2024 (12+)	Approved Nov 2023	Approved Jan 2024	EU/Japan approved before US
Nemolizumab (IL-31)	Approved Dec 2024 (AD, 12+)	Approved	Approved (incl. AD itch)	Itch-focused; with topical steroids/TCI
Upadacitinib (oral JAK)	Approved (12+); boxed warning	Approved	Approved	Class boxed warning everywhere
Abrocitinib (oral JAK)	Approved (12+); boxed warning	Approved	Approved	Class boxed warning everywhere
Baricitinib (oral JAK)	Not approved for AD	Approved for AD	Approved for AD	Notable US–vs–EU/Japan difference
Topical ruxolitinib	Approved (12+)	Approved	Approved	Class boxed warning on label; BSA/duration limits
Roflumilast cream	0.15% (6+), 0.05% (2–5)	Region-dependent	Region-dependent	Steroid-free PDE4
Tapinarof cream	Approved (2+)	Region-dependent	Region-dependent	Steroid-free; no BSA/duration limit

Approval details and brand names change and differ by country; confirm current local status with your clinician or national regulator.

Atopic dermatitis often changes during pregnancy — in some women it improves (driven by the immune shift during pregnancy toward a Th2-dominant state), while in others it worsens, particularly in the first and second trimesters. Either pattern is possible and neither is harmful to the pregnancy itself. Planning ahead with your dermatologist is key.

Topical treatments in pregnancy: Emollients and moisturizers are safe throughout pregnancy and breastfeeding — they are first-line and should not be stopped. Low- to mid-potency TCS are considered generally safe for short-term localized use; avoid high-potency preparations over large body surface areas or under prolonged occlusion. Tacrolimus and pimecrolimus topically have limited data but are generally considered lower risk than high-potency systemic steroids; most guidelines note insufficient evidence rather than a clear prohibition. Crisaborole, ruxolitinib cream, and tapinarof: inadequate human pregnancy data — discuss risk-benefit with your dermatologist and OB. Non-steroidal topicals are preferred over escalating TCS potency during pregnancy.

Dupilumab in pregnancy: Human data are limited but reassuring so far — the LIBERTY AD registry has enrolled pregnant women and early reports do not signal a teratogenic effect. IgG antibodies cross the placenta in the third trimester, so theoretically the fetus could have brief dupilumab exposure. Most guidelines classify dupilumab as acceptable if the maternal benefit clearly outweighs theoretical risk (e.g., severe disease that cannot be controlled without it). Do NOT stop dupilumab abruptly without discussing with your care team — an uncontrolled AD flare in pregnancy carries its own risks (poor sleep, stress, potential need for high-dose systemic steroids). The dupilumab prescribing information includes a pregnancy registry; your team can enroll you if you become pregnant while on it.

JAK inhibitors and pregnancy: JAK inhibitors are NOT recommended in pregnancy based on animal reproductive toxicity data showing embryotoxic effects at doses comparable to human therapeutic exposures. Reliable contraception is required for all patients of childbearing potential on oral JAK inhibitors. If planning a pregnancy, discuss transitioning to a biologic before trying to conceive.

Breastfeeding: TCS and emollients are safe during breastfeeding. Dupilumab is an IgG antibody; some is excreted in breast milk, but oral bioavailability of proteins in milk is negligible, so infant exposure through breastfeeding is expected to be minimal. Most dermatologists consider dupilumab compatible with breastfeeding, but document the discussion. JAK inhibitors are not recommended during breastfeeding due to presence in milk in animal studies.

Does the baby inherit AD? Yes, at increased rates — if one parent has AD, asthma, or allergic rhinitis, the risk to offspring is ~30%; if both parents are affected, ~50–70%. Early, consistent moisturizing of newborn skin (the “BARRIER” trial and related studies) shows modest reduction in AD development in high-risk infants. Early food introduction per the LEAP protocol (early peanut introduction for high-risk infants with severe eczema) reduces peanut allergy risk.

For some people with AD, the biggest driver of ongoing disease is not internal genetics but external exposures. Irritant contact dermatitis (from repeated exposure to detergents, solvents, wet work, or friction) and allergic contact dermatitis (an immune reaction to a specific allergen) can both worsen AD or look like AD. Distinguishing them is important because the treatment strategy differs.

High-risk occupations:

Healthcare workers: Frequent handwashing, disinfectants, and latex exposure (though latex-free gloves are now standard) are major drivers of hand eczema. The switch to powderless gloves and latex-free alternatives has reduced occupational allergic contact dermatitis in healthcare, but irritant dermatitis from excessive handwashing and soap remains common.
Hairdressers and cosmetologists: Paraphenylenediamine (PPD) in hair dyes, persulfates in bleach, and glyceryl thioglycolate in perms are leading contact sensitizers. Once sensitized, even retail hair dye use at home causes reactions.
Food service and catering: Wet work, flour proteins, citrus juices, garlic, and spices are common occupational sensitizers. Hand eczema is near-universal.
Cleaners and janitors: Disinfectants, rubber chemicals (in gloves), and floor-care products are primary triggers.
Construction and metalworkers: Chromate (in cement), cobalt, nickel, and epoxy resins are potent sensitizers.

What you can do: If you suspect occupational exposure is driving your disease, a dermatologist can arrange patch testing to identify specific allergens. Barrier creams applied before exposure, cotton glove liners inside protective gloves, and minimizing wet-work time can all reduce trigger burden. Occupational dermatology is a subspecialty that can provide workplace-accommodation letters and assist with workers’ compensation if needed. In some cases, a job modification or change is necessary — this is a significant decision that should be made with proper dermatologic advice and documentation.

Personal care products as hidden triggers: Many people with AD are sensitized to ingredients in their own skin-care products. Common culprits include fragrance mixes (present in many creams, washes, and cosmetics even when marketed as “gentle”), methylisothiazolinone preservative, and formaldehyde releasers (diazolidinyl urea, quaternium-15). If your eczema worsens after adding a new moisturizer or soap, contact dermatitis from that product is worth investigating before assuming treatment failure.

Exercise has well-established benefits for mental health, cardiovascular health, and immune regulation — but for people with AD, sweat, friction, and environmental exposures during sports can temporarily worsen itch and flares. The benefits of staying active almost always outweigh the skin challenges, and these strategies help manage them.

Exercise-associated itch flares: Sweating activates cholinergic nerve fibers, and sweat composition (particularly the protein dermcidin, which S. aureus degrades) can both irritate and sensitize already-compromised AD skin. Strategies:

Shower immediately after exercise using cool or lukewarm water and a mild, fragrance-free cleanser.
Apply emollient within 3 minutes of showering.
Wear loose-fitting, moisture-wicking clothing during exercise (merino wool or synthetic moisture-wicking fabrics are better than cotton, which retains sweat against the skin).
Avoid exercising outdoors on high-pollen days if aeroallergens are a known trigger.
For gym workouts: wipe down equipment before use (contact with other people’s sweat/bacteria can trigger reactions).

Swimming: Chlorine and bromide in pools are irritating to AD skin, and saltwater can be drying. However, many patients with AD actually find swimming beneficial, particularly in saltwater (similar to natural mineral water), and the antimicrobial effect of pool chlorine is similar to a dilute bleach bath. Practical approach: rinse thoroughly with fresh water immediately after swimming; apply emollient promptly. If chlorine consistently worsens your skin, barrier creams (petroleum jelly) applied to active areas before swimming can reduce chlorine penetration.

Skin protection during sports: Friction from sports equipment (helmets, padding, jersey fabric) can Koebnerize eczema (trigger flares at friction sites). Moisture-wicking base layers reduce friction; silicone-based barrier creams protect specific friction zones.

Traveling: Travel introduces variable humidity (airplane cabins run at 5–10% humidity — extremely drying), different water hardness, climate changes, and disruption to your skincare routine. Packing essentials: your emollient and topical medications in carry-on (in approved liquid volumes), hypoallergenic travel-sized product versions, and a written summary of your medications for international travel (especially for biologic pen devices at airport security). Extremes of heat and humidity can both worsen AD; acclimatization usually takes a few days. If traveling to high-sun climates, be aware that phototherapy-like UV exposure can help some AD patients but sunburn is an inflammatory trigger — use a non-fragranced broad-spectrum sunscreen.

Atopic dermatitis treatments span an enormous cost range — from inexpensive generic TCS and vaseline (cents per dose) to biologics and JAK inhibitors that list for $20,000–$40,000 per year. Insurance coverage, prior authorizations, step therapy requirements, and manufacturer patient assistance programs collectively determine what patients actually pay. Understanding this landscape upfront prevents abandonment of effective therapy.

Step therapy (fail-first) requirements: Nearly all commercial insurance and Medicare plans require documented failure of lower-cost treatments before approving advanced therapies. Typical step requirements for dupilumab and JAK inhibitors include failure of at least 2 topical treatments (TCS + a non-steroidal topical or TCI) over a defined duration (often 3–6 months), plus potentially a trial of phototherapy. Work with your dermatologist to document all prior treatment attempts in detail — inadequate documentation is the most common cause of prior authorization denials. Many states have enacted step therapy override laws that require insurers to grant exceptions when the step therapy requirement is medically inappropriate; your dermatologist can submit an override request.

Manufacturer copay assistance (commercial insurance):

Dupixent (dupilumab) — Dupixent MyWay program: eligible commercially insured patients may pay as little as $0/month; program covers the gap between insurance payment and patient cost share up to an annual maximum. Call 1-844-DUPIXENT or visit dupixentmyway.com.
Adbry (tralokinumab) — AbbVie/LEO Care program: copay assistance available; contact LEO Pharma at 1-833-LEO-CARE.
Ebglyss (lebrikizumab) — Lilly Cares Foundation: copay assistance and income-based free-drug programs; 1-800-545-5979.
Nemluvio (nemolizumab) — Galderma patient support: contact Galderma at 1-866-735-4137 for access program details.
Rinvoq (upadacitinib) — AbbVie myAbbVie Assist: free drug for uninsured/underinsured patients; commercial copay card available; 1-800-222-6885.
Cibinqo (abrocitinib) — Pfizer RxPathways: copay card and patient assistance; 1-844-989-PATH.
Olumiant (baricitinib, EU/JP only for AD) — Lilly patient assistance: for US-covered indications only via Lilly Cares Foundation.

Important: manufacturer copay cards cannot be used with Medicare or Medicaid (federal anti-kickback regulations). For Medicare Part D beneficiaries, Extra Help (LIS) programs and State Pharmaceutical Assistance Programs (SPAPs) are alternatives.

Free drug programs for uninsured/underinsured: All major manufacturers offer income-based patient assistance programs (PAPs) that provide free drug to qualifying patients. Income thresholds vary (typically 3–5× federal poverty level). Your dermatology office social worker, or organizations like NeedyMeds (needymeds.org), can help identify the right program and complete applications. Processing time: typically 2–4 weeks.

Biosimilars (emerging): Multiple dupilumab biosimilars are in Phase 3 development and regulatory filing stages. Once approved (anticipated 2026–2028 in the US and EU), biosimilar dupilumab is expected to significantly reduce costs. Biosimilars are not bioidentical generics but must demonstrate clinical equivalence; they will carry the same safety profile as the reference product.

Non-drug cost management: Moisturizers and emollients are an ongoing cost for AD. Prescription emollients (Atopiclair, EpiCeram, etc.) are often covered by insurance and may be more cost-effective than purchasing OTC moisturizers out-of-pocket. Large tubs of plain petroleum jelly or generic ceramide-based cream are highly effective and the most economical first-line emollient. Many patients find that adequate emollient use reduces the overall cost of disease by reducing flare frequency and the amount of prescription topical needed.

Questions to ask your dermatologist:

Is my insurance likely to require step therapy for this medication?
Does your office have a prior authorization coordinator who can help with appeals?
Am I eligible for a manufacturer copay program?
Are there clinical trials I might qualify for that would cover my medication cost?

Specialty Center Directory

Always call to confirm services, locations, and whether a referral is needed. Phone numbers are main lines and may change.

Mountain West & Utah

University of Utah Health — Department of Dermatology (Salt Lake City). Comprehensive AD care including phototherapy, biologics, oral JAK inhibitors, pediatric dermatology, and clinical trials. Main: 801-581-2955.
Intermountain Health — Dermatology & Allergy clinics (Wasatch Front and across Utah). Eczema care, phototherapy, and biologic/systemic management. Find a provider: 866-415-6919.
Primary Children’s Hospital (Salt Lake City) — Pediatric Dermatology & Allergy for childhood eczema and the atopic march (asthma, food allergy). Main: 801-662-1000.

US National Centers of Excellence (examples)

Icahn School of Medicine at Mount Sinai, New York — major AD research/treatment center. 212-241-9728 (Dermatology).
Northwestern Medicine, Chicago — eczema/itch programs. 312-695-8106.
Oregon Health & Science University (OHSU), Portland — AD trials and care. 503-418-3376.
University of California San Diego / Rady Children’s — pediatric AD. 858-966-1700.
Most academic dermatology departments have an “eczema” or “complex medical dermatology” clinic — ask your local center.

Veterans (VA)

George E. Wahlen VA Medical Center (Salt Lake City) — Dermatology service for veterans, including AD care. Main: 801-582-1565. Eczema may be evaluated for service connection in some veterans; ask your VA primary-care team and a Veterans Service Officer about eligibility and benefits.

Canada

Academic dermatology centers (e.g., in Toronto, Vancouver, Montreal) offer biologics and JAK inhibitors for AD. Coverage runs through provincial drug plans plus private insurance; biologics/JAK inhibitors often require special-authority approval. The Canadian Dermatology Association and Eczema Society of Canada provide patient resources and coverage guidance.

International (key global resources)

International Eczema Council and the EuroGuiDerm/EADV network (Europe) — clinician guidance with international reach.
National eczema charities (e.g., UK’s National Eczema Society, Eczema Society of Canada, Eczema Association of Australasia) offer education and support.

Organizations & education

National Eczema Association — nationaleczema.org (education, product guidance, peer support, financial-assistance information, trials).
American Academy of Dermatology — aad.org (find a dermatologist; patient education).
ClinicalTrials.gov — search and contact active trials.
Specialty pharmacies at University of Utah and Intermountain — biologic injection teaching and help with drug approvals and patient-assistance programs.

Track: flare frequency and locations; worst-itch score (0–10); nights of disrupted sleep; what seemed to trigger flares; how much moisturizer/medicine you actually used; photos of problem areas; effect on work/school/mood.
Bring: a current list of all products and medicines (including supplements), your questions (use the lists above), and your top goal for the visit.
Ask for: written instructions on strengths, amounts (fingertip units), and a proactive maintenance plan; and a clear “what to do if it flares/gets infected” plan.

Atopic / atopy — the allergic tendency that links eczema, asthma, and hay fever.
Atopic march — the pattern of developing eczema, then sometimes food allergy, asthma, and hay fever.
Biologic — an antibody medicine (injection) that blocks a specific immune signal.
BSA — body surface area; the percent of skin affected.
Calcineurin inhibitor — a steroid-free anti-inflammatory cream/ointment (tacrolimus, pimecrolimus).
Conjunctivitis — eye inflammation (red, itchy, gritty eyes); a possible biologic side effect.
EASI / SCORAD / IGA — clinician scores of eczema severity.
Eczema herpeticum — a serious herpes-virus infection of eczema skin; an emergency.
Emollient — moisturizer.
Filaggrin — a skin-barrier protein; genetic changes in it raise eczema risk.
Fingertip unit (FTU) — a measure for how much topical to apply.
Flare — a worsening of eczema.
IL-4, IL-13, IL-31 — immune signaling proteins that drive eczema inflammation and itch; the targets of modern biologics.
JAK inhibitor — a medicine (pill or cream) that blocks Janus-kinase signaling.
Lichenification — thickened, leathery skin from chronic rubbing.
NB-UVB — narrowband ultraviolet B phototherapy.
POEM — a patient-reported eczema symptom questionnaire.
Proactive therapy — applying anti-inflammatory medicine (often twice weekly) to hot spots after clearing, to prevent flares.
Soak and seal — bathe, then moisturize promptly to lock in water.
Type-2 inflammation — the branch of the immune system overactive in eczema.

AAD 2023–2024 Guidelines on the management of atopic dermatitis in adults (topicals; and phototherapy/systemic therapies including biologics and JAK inhibitors), plus AAD pediatric AD guidance.
EuroGuiDerm/EADV guideline on atopic eczema (European).
FDA/EMA/PMDA labels for dupilumab, tralokinumab, lebrikizumab, nemolizumab, upadacitinib, abrocitinib, topical ruxolitinib, crisaborole, roflumilast cream, and tapinarof cream.
Pivotal trials referenced above (LIBERTY AD/SOLO/CHRONOS/CAFÉ; ECZTRA; ADvocate/ADhere; ARCADIA; Measure Up/AD Up/Heads Up; JADE; TRuE-AD; INTEGUMENT; ADORING).
National Eczema Association and International Eczema Council patient and clinician resources.

Guidelines and approvals evolve; this guide reflects information available as of June 2026. Verify current details with your clinician and official sources.

Final reminder. This guide is educational and does not replace personalized medical care. Bring your questions to a qualified clinician who can examine you, weigh your full history, and tailor treatment to you. For painful, rapidly spreading blistering with fever — possible eczema herpeticum — seek urgent care.

A Research Guide for
Atopic Dermatitis

⚡ Quick Start — If You Read Nothing Else

Understanding Atopic Dermatitis: What It Is and Why You Itch

Where eczema shows up (and how it changes with age)

How “how bad is it?” gets measured

Stage 1 — Daily Skin-Barrier Care & Topical Medicines (the Foundation)

Moisturizers (emollients): the non-negotiable base

Find and reduce your triggers

Topical corticosteroids (“steroid creams”): used right, they’re safe and effective

Steroid-free (nonsteroidal) topical medicines

Wet-wrap therapy for tough flares

Stage 2 — Phototherapy (Light Treatment)

What to expect

Stage 3 — Biologic Injections & Oral JAK Pills (for Moderate-to-Severe Disease)

Biologic injections: precise, well-tolerated, no routine blood tests

Oral JAK-inhibitor pills: fast and effective — with serious warnings

Older (“conventional”) systemic medicines

Stage 4 — Managing Itch, Sleep, and Skin Infections

Breaking the itch-scratch cycle

Sleep

Skin infections: recognize and treat promptly

Stage 5 — Eczema in Children, the Atopic March, and Living Well

Eczema in babies and children

The atopic march

Mental health and the emotional toll

School, work, and daily life

Pregnancy and breastfeeding

Support & Resources

Clinical Trials — how to find them and what’s out there

Failed or De-adopted Therapies — honest answers to claims you’ll see online

International Access & Regulatory Landscape

Specialty Center Directory

Mountain West & Utah

US National Centers of Excellence (examples)

Veterans (VA)

Canada

International (key global resources)

Organizations & education

Important Safety Warnings: JAK Inhibitors for Atopic Dermatitis

A Research Guide forAtopic Dermatitis

⚡ Quick Start — If You Read Nothing Else

Understanding Atopic Dermatitis: What It Is and Why You Itch

Where eczema shows up (and how it changes with age)

How “how bad is it?” gets measured

Stage 1 — Daily Skin-Barrier Care & Topical Medicines (the Foundation)

Moisturizers (emollients): the non-negotiable base

Find and reduce your triggers

Topical corticosteroids (“steroid creams”): used right, they’re safe and effective

Steroid-free (nonsteroidal) topical medicines

Wet-wrap therapy for tough flares

Stage 2 — Phototherapy (Light Treatment)

What to expect

Stage 3 — Biologic Injections & Oral JAK Pills (for Moderate-to-Severe Disease)

Biologic injections: precise, well-tolerated, no routine blood tests

Oral JAK-inhibitor pills: fast and effective — with serious warnings

Older (“conventional”) systemic medicines

Stage 4 — Managing Itch, Sleep, and Skin Infections

Breaking the itch-scratch cycle

Sleep

Skin infections: recognize and treat promptly

Stage 5 — Eczema in Children, the Atopic March, and Living Well

Eczema in babies and children

The atopic march

Mental health and the emotional toll

School, work, and daily life

Pregnancy and breastfeeding

Support & Resources

Clinical Trials — how to find them and what’s out there

Failed or De-adopted Therapies — honest answers to claims you’ll see online

International Access & Regulatory Landscape

Specialty Center Directory

Mountain West & Utah

US National Centers of Excellence (examples)

Veterans (VA)

Canada

International (key global resources)

Organizations & education

Important Safety Warnings: JAK Inhibitors for Atopic Dermatitis

A Research Guide for
Atopic Dermatitis